Eurobio Scientific S.A. (ALERS.PA)
Eurobio Scientific S.A. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Les Ulis, IF, FR. The stock last traded at $20.80, down 0.48% on the session, giving a market capitalisation of $209.4M. Its beta of 0.70 implies it has historically moved less than the broad market.
Eurobio Scientific S.A. specializes in the conceptualization, development, and distribution of sophisticated diagnostic products. Its key therapeutic and research domains include transplantation, infectious illnesses, life sciences, and oncology. The company's portfolio features the Tetanus Quick Stick, an essential emergency diagnostic for rapidly determining a patient's tetanus vaccination status. It also distributes cell culture media, molecular biology reagents, and proprietary antibody solutions. Proprietary developments from Eurobio Scientific encompass the BJI InoPlex, a multiplex serological test for diagnosing prosthetic joint infections, and the EBX-044 PCR test, utilized for identifying SARS-CoV-2 variants. Its licensed offerings include AlloMap, a gene-expression profiling blood test designed for the ongoing surveillance of heart transplant recipients. The firm, initially named Diaxonhit, changed its corporate identity to Eurobio Scientific S.A. in June 2018. Founded in 1997, the company is headquartered in Les Ulis, France.
Eurobio Scientific S.A. is most often compared with the following Healthcare names: